Top

American Journal of Clinical Dermatology

Published in:

15-03-2023 | Phototherapy | Review Article

Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)

Authors: Tala B. Shahin, Shreya A. Sreekantaswamy, Jason E. Hawkes, Daniel C. Butler

Published in: American Journal of Clinical Dermatology | Issue 3/2023

Abstract

Chronic eczematous eruptions of aging (CEEA) refers to a heterogenous group of longstanding, pruritic eczematous dermatoses with an unidentified etiology, or those which do not meet strict disease criteria. The literature has not yet established a single ubiquitous disease or term for these eruptions in adults over the age of 65 years. Instead, CEEA is attributed various names, including immunologic eruption of aging, and eruption of immunosenescence. Atopic dermatitis in the elderly, eczema in the elderly, and late- or adult-onset atopic dermatitis or eczema likely also fall under the umbrella of CEEA, given that older patients often do not meet strict criteria for atopic dermatitis. As a reflection of such terminological heterogeneity, CEEA does not have a standardized workup algorithm. This lack of uniformity can obscure the ability to study and understand appropriate treatments for this condition. Yet, as providers become increasingly aware of CEEA and more comfortable in making this diagnosis in older adults, it is necessary that dermatologists understand the safety and efficacy of common CEEA treatments in this population. Here, we discuss special considerations, challenges, and recommendations for treating older adults with CEEA with topical and systemic therapeutics. We provide an overview of therapeutic strategies and potential barriers to treatment and discuss the essential role of shared decision making when caring for this patient population.

Morin C, Joly P, Courville P, Young P, Richard C, Balguerie X, et al. Chronic eczematiform eruption in the elderly. Ann Dermatol Venereol. 2002;2002:19–22.

Joly P, Benoit-Corven C, Lambert A, Hellot M, Josset V, Barbaud A, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case–control study. J Invest Dermatol. 2007;127(12):2766–71.PubMedCrossRef

Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149(7):814–8.PubMedCrossRef

Abel MK, Jelousi S, Berger T, Murase JE, Butler DC. Immunological eruptions of ageing: reframing chronic pruritic rashes in older adults. Br J Dermatol. 2021;185(3):638–9.PubMedCrossRef

Berger TG, Steinhoff M. Pruritus in elderly patients—eruptions of senescence. Semin Cutan Med Surg. 2011;30(2):113–7.PubMedPubMedCentralCrossRef

Tanei R. Clinical characteristics, treatments, and prognosis of atopic eczema in the elderly. J Clin Med. 2015;4(5):979–97.PubMedPubMedCentralCrossRef

Tétart F, Joly P. Eczema in elderly people. Eur J Dermatol. 2020;30(6):663–7.PubMedCrossRef

Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526-32.e7.PubMedCrossRef

Laube S. Skin infections and ageing. Ageing Res Rev. 2004;3(1):69–89.PubMedCrossRef

10.

Beckman AGK, Parker MG, Thorslund M. Can elderly people take their medicine? Patient Educ Couns. 2005;59(2):186–91.PubMedCrossRef

11.

Lisberg R,Higham C, Jayson M. Problems for rheumatic patients in opening dispensed drug containers. Br J Rheumatol. 1983;22(2):95–8.

12.

Arlt S, Lindner R, Rösler A, von Renteln-Kruse W. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033–47.PubMedCrossRef

13.

Joray S, Wietlisbach V, Büla C. Cognitive impairment in elderly medical inpatients: detection and associated six-month outcomes. Am J Geriatr Psychiatry. 2004;12(6):639–47.PubMed

14.

Wilson IB, Schoen C, Neuman P, Strollo MK, Rogers WH, Chang H, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America’s seniors. J Gen Intern Med. 2007;22(1):6–12.PubMedPubMedCentralCrossRef

15.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.PubMedCrossRef

16.

Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.PubMedCrossRef

17.

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef

18.

Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff. 2003;22(4):220–9.CrossRef

19.

Farage MA, Miller KW, Sherman SN, Tsevat J. Assessing quality of life in older adult patients with skin disorders. Glob J Health Sci. 2012;4(2):119–31.PubMedPubMedCentralCrossRef

20.

Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.PubMedCrossRef

21.

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.PubMedCrossRef

22.

Pieterse AH, Finset A. Shared decision making—much studied, much still unknown. Patient Educ Couns. 2019;102(11):1946–8.PubMedCrossRef

23.

Katsarou A, Armenaka MC. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25(1):12–8.PubMedCrossRef

24.

Lima AL, Timmermann V, Illing T, Elsner P. Contact dermatitis in the elderly: predisposing factors, diagnosis, and management. Drugs Aging. 2019;36(5):411–7.PubMedCrossRef

25.

Zirwas MJ, Barkovic S. Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream. J Drugs Dermatol. 2017;16(3):243–7.PubMed

26.

Fowler JF, Nebus J, Wallo W, Eichenfield L. Colloidal oatmeal formulations as adjunct treatments in atopic dermatitis. J Drugs Dermatol. 2012;11(7):804–7.PubMed

27.

Katoh N, Tennstedt D, Abellan van Kan G, Saint Aroman M, Loir A, Bacqueville D, et al. Gerontodermatology: the fragility of the epidermis in older adults. Journal of the European Academy of Dermatology and Venereology. 2018;32(S4):1–20.

28.

Rathi SK, D’Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251–9.PubMedPubMedCentralCrossRef

29.

Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Investig Dermatol. 1988;90(4):532–5.PubMedCrossRef

30.

May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch Intern Med. 1976;136(5):612–3.PubMedCrossRef

31.

Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol. 1976;112(11):1559–62.PubMedCrossRef

32.

Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460–4.PubMedPubMedCentralCrossRef

33.

Valeant Pharmaceuticals North America LLC. Elidel (pimecrolimus) Cream [package insert]. 2014 [cited 2020 November 12]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021302s018lbl.pdf. Accessed 8 Aug 2021.

34.

Astellas Pharma US. Protopic (tacrolimus) [package insert]. 2011 [cited 2020 November 12]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf. Accessed 8 Aug 2021.

35.

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82.PubMedCrossRef

36.

Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163(1):70–7.PubMedCrossRef

37.

Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. JAAD. 2014;71(1):116–32.

38.

Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Investig Dermatol. 1996;107(1):51–6.PubMedCrossRef

39.

Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274–89.PubMedCrossRef

40.

Pfizer. Eucrisa (crisaborole ointment) [package insert]. 2016 [cited 2020 November 9]. http://labeling.pfizer.com/ShowLabeling.aspx?id=5331#section-11. Accessed 8 Aug 2021.

41.

Labib A, Does AV, Korbutov J, Yosipovitch G. Silicone barrier cream in treatment of atopic dermatitis: a literature review. Dermatol Ther. 2022;35(12): e15884.PubMedCrossRef

42.

Panther DJ, Jacob SE. The importance of acidification in atopic eczema: an underexplored avenue for treatment. J Clin Med. 2015;18(4):970–8.CrossRef

43.

Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23.PubMedCrossRef

44.

Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol. 1995;154(9):4851.PubMedCrossRef

45.

Powell JB, Gach JE. Phototherapy in the elderly. Clin Exp Dermatol. 2015;40(6):605–10.PubMedCrossRef

46.

NICE Clinical Guideline. Psoriasis: assessment and management. [cited 2020 November 2]. https://www.nice.org.uk/guidance/cg153. Accessed 8 Aug 2021.

47.

Gloor M, Scherotzke A. Age dependence of ultraviolet light-induced erythema following narrow-band UVB exposure. Photodermatol Photoimmunol Photomed. 2002;18(3):121–6.PubMedCrossRef

48.

Yaar M, Gilchrest BA. Ageing and photoageing of keratinocytes and melanocytes. Clin Exp Dermatol. 2001;26(7):583–91.PubMedCrossRef

49.

Hawk JLM. Photosensitivity in the elderly. Br J Dermatol. 1990;122(35):29–41.PubMedCrossRef

50.

Dennis M, Bhutani T, Koo J, Liao W. Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. J Dermatol Treat. 2013;24(1):2–6.CrossRef

51.

Storan ER, McEvoy MT, Wetter DA, El-Azhary RA, Bridges AG, Camilleri MJ, et al. Filling a critical practice gap: experience with a dermatology day treatment center at Mayo Clinic. Int J Dermatol. 2015;54(5):600–4.PubMedCrossRef

52.

DAVA Pharmaceuticals Inc. Methotrexate [package insert]. 2016 [cited 2020 November 2]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf. Accessed 8 Aug 2021.

53.

Kursewicz C., Valdes-Rodriguez R, Yosipovitch G. Methotrexate in the treatment of chronic itch in the geriatric population. Acta Derm Venereol. 2020;100(1):1–2. https://doi.org/10.2340/00015555-3360

54.

Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J. 2008;10(6):413–4.PubMed

55.

Nedelcu R-I, Balaban M, Turcu G, Brinzea A, Ion DA, Antohe M, et al. Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: three case reports. Exp Ther Med. 2019;18(2):905–10.PubMedPubMedCentral

56.

Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. JAAD. 2014;71(2):327–49.

57.

Paul MA, Jorizzo JL, Fleischer AB, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. JAAD. 1994;31(4):620–5.PubMedCrossRef

58.

Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J. 2000;76(902):787.PubMedPubMedCentralCrossRef

59.

Tanei R. Atopic dermatitis in older adults: a review of treatment options. Drugs Aging. 2020;37(3):149–60.PubMedPubMedCentralCrossRef

60.

Horizon Pharma USA. RAYOS (prednisone) [package insert]. 1955 [cited 2020 December 9]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202020s000lbl.pdf. Accessed 8 Aug 2021.

61.

Shionogi Pharma. Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets) [package insert]. 2010 [cited 2020 December 9]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf. Accessed 8 Aug 2021.

62.

Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, et al. INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids. J Clin Exp Hepatol. 2018;8(4):403–31.PubMedPubMedCentralCrossRef

63.

Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3.PubMedCrossRef

64.

Marcum ZA, Hanlon JT. Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults. Ann Longterm Care. 2010;18(9):24–7.PubMedPubMedCentral

65.

American Geriatrics Society. 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.

66.

Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.PubMedPubMedCentralCrossRef

67.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37.PubMedCrossRef

68.

Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. JAAD. 2017;76(1):1–9.PubMedCrossRef

69.

Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):e232.CrossRef

70.

Hawkes J, Duffin K. Erythrodermic psoriasis in adults. 2020 [cited 2021 January 30]. https://www.uptodate.com/contents/erythrodermic-psoriasis-in-adults. Accessed 8 Aug 2021.

71.

Food and Drug Administration. Neoral Drug Information. 2009 [cited 2020 November 9]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf. Accessed 8 Aug 2021.

72.

Prometheus Laboratories. Imuran (azathioprine) [package insert]. 2011 [cited 2020 November 11]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016324s034s035lbl.pdf. Accessed 8 Aug 2021.

73.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.PubMedCrossRef

74.

Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5.PubMedPubMedCentralCrossRef

75.

Dharmasiri S, Johnson H, McLaughlin S, Weaver S. PTU-109 azathioprine in the elderly—is it tolerated and is it safe? Gut. 2014;63(Suppl 1):A87.CrossRef

76.

Genentech USA. Cellcept (mycophenolate mofetil) [package insert]. 2018 [cited 2020 November 14]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050722s035,050723s035,050758s033,050759s041lbl.pdf. Accessed 8 Aug 2021.

77.

Aventis Pharmaceuticals Inc. Allegra (fexofenadine hydrochloride) [package insert]. 2006 [cited 2020 December 9]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20786se8-014,20872se8-011,20625se8-012_allegra_lbl.pdf. Accessed 8 Aug 2021.

78.

Baghoomian W, Na C, Simpson EL. New and emerging biologics for atopic dermatitis. Am J Clin Dermatol. 2020;21(4):457–65.PubMedCrossRef

79.

Regeneron Pharmaceuticals. Dupixent (dupilumab) [package insert]. 2017 [cited 2020 November 9]. https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf. Accessed 8 Aug 2021.

80.

Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol. 2020;45(7):888–90.PubMedCrossRef

81.

Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–6.PubMedCrossRef

82.

He H, Guttman-Yassky E. JAK Inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–92.PubMedCrossRef

83.

Pfizer Labs. Cibinqo (abrocitinib) [package insert]. 2022 [cited 2023 January 1].

84.

Abbvie Inc. Rinvoq (upadacitinib) [package insert]. 2022 [cited 2023 January 1].

85.

Lilly USA. Olumiant (baricitinib) [package insert]. 2018 [cited 2021 January 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf. Accessed 8 Aug 2021.

86.

Pfizer. Xeljanz (tofacitinib) [package insert]. 2012 [cited 2021 January 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf. Accessed 8 Aug 2021.

87.

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus Kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9.PubMedPubMedCentralCrossRef

88.

Pfizer. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ^® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA). 2021.

89.

Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–62.PubMedCrossRef

90.

Incyte Corporation. Opzelura (ruxolitinb) [package insert]. 2022 [cited 2023 Feburary 12]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215309s001lbl.pdf. Accessed 8 Aug 2021.

91.

Dhillon S. Delgocitinib: first approval. Drugs. 2020;80(6):609–15.PubMedCrossRef

92.

Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. JAMA Dermatol. 2020;156(11):1240–5.PubMedCrossRef

93.

Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–86.PubMedCrossRef

94.

Eli Lilly and Company. A Study of Baricitinib (LY3009104) in PatientsWith Moderate to Severe Atopic Dermatitis (BREEZE-AD1) (ClinicalTrials.gov Identifier: NCT03334396). 2020 [cited 2020 November 9]. https://clinicaltrials.gov/ct2/show/results/NCT03334396?view=results#wrapper. Accessed 8 Aug 2021.

95.

Eli Lilly Company. Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD2) (ClinicalTrials.gov Identifier: NCT03334422).2020 [cited 2020 November 9]; Available from: https://clinicaltrials.gov/ct2/show/results/NCT03334422. Accessed 8 Aug 2021.

Title: Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)
Authors: Tala B. Shahin
Shreya A. Sreekantaswamy
Jason E. Hawkes
Daniel C. Butler
Publication date: 15-03-2023
Publisher: Springer International Publishing
Keywords: Phototherapy
Atopic Dermatitis
Pruritus
Published in: American Journal of Clinical Dermatology / Issue 3/2023
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-023-00767-7

At a glance: The STEP trials

Springer Medicine

Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Effects of Exercise and Dietary Modifications on Hidradenitis Suppurativa: A Systematic Review

Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis

Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know

Muir–Torre Syndrome: A Cutaneous Finding Amidst Broader Malignancies